doravirine/islatravir (MK-8591A) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
doravirine/islatravir (MK-8591A) / Merck (MSD)
MK-8591A-018, NCT04223791 / 2019-000587-23: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
643
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL, Placebo to MK-8591A
Merck Sharp & Dohme LLC
HIV Infection
08/21
02/25
MK-8591A-017, NCT04223778 / 2019-000586-20: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1

Completed
3
672
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, ART
Merck Sharp & Dohme LLC
HIV Infection
09/21
08/24
MK-8591A-020, NCT04233879 / 2019-000590-23: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Completed
3
599
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir, BIC/FTC/TAF, Bictegravir/emtricitabine/tenofovir alafenamide, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
01/25
MK-8591A-019, NCT04233216 / 2019-000588-26: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Completed
3
35
Europe, Canada, Japan, US, RoW
ISL, Islatravir, MK-8591, DOR, Doravirine, MK-1439, DOR/ISL, Doravirine/Islatravir, MK-8591A, Placebo to ISL, Placebo to DOR
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
11/23
MK-8591A-051, NCT05631093: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART)

Active, not recruiting
3
553
Europe, Canada, Japan, US, RoW
ART, DOR/ISL, MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/24
07/28
MK-8591A-052, NCT05630755: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
514
Europe, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/Islatravir, BIC/FTC/TAF, Bictegravir/Emtricitabine/Tenofovir Alafenamide, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
10/24
08/28
MK-8591A-033, NCT04776252 / 2020-001191-14: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

Active, not recruiting
3
2000
Europe, Canada, Japan, US, RoW
MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/27
10/27
NCT05705349: DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
Merck Sharp & Dohme LLC
HIV-1 Infection
10/25
08/29
MK-8591A-054, NCT05766501: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir
Merck Sharp & Dohme LLC
HIV Infection
12/25
09/28
MK-8591A-028, NCT04295772 / 2019-003597-10: Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg

Completed
2
42
Europe, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir
Merck Sharp & Dohme LLC
HIV-1 Infection
12/21
01/23
2017-000437-32: Dose Ranging Trial of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine (3TC)

Not yet recruiting
2
120
Europe
MK-8591, Doravirine, Doravirine/Lamivudine/Tenofovir disoproxil fumarate, Epivir, MK-8591A, MK-8591, MK-1439, MK-1439A, MK-8591A, Capsule, Film-coated tablet, Epivir
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT06719570: A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Completed
1
24
US
MK-8591A, Doravirine/Islatravir (DOR/ISL) Fixed-Dose Combination (FDC), Islatravir, MK-8591, ISL, Doravine, MK-1439, DOR
Merck Sharp & Dohme LLC
Healthy
03/24
03/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
doravirine/islatravir (MK-8591A) / Merck (MSD)
MK-8591A-018, NCT04223791 / 2019-000587-23: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
643
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL, Placebo to MK-8591A
Merck Sharp & Dohme LLC
HIV Infection
08/21
02/25
MK-8591A-017, NCT04223778 / 2019-000586-20: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1

Completed
3
672
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, ART
Merck Sharp & Dohme LLC
HIV Infection
09/21
08/24
MK-8591A-020, NCT04233879 / 2019-000590-23: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Completed
3
599
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir, BIC/FTC/TAF, Bictegravir/emtricitabine/tenofovir alafenamide, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
01/25
MK-8591A-019, NCT04233216 / 2019-000588-26: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Completed
3
35
Europe, Canada, Japan, US, RoW
ISL, Islatravir, MK-8591, DOR, Doravirine, MK-1439, DOR/ISL, Doravirine/Islatravir, MK-8591A, Placebo to ISL, Placebo to DOR
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
11/23
MK-8591A-051, NCT05631093: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART)

Active, not recruiting
3
553
Europe, Canada, Japan, US, RoW
ART, DOR/ISL, MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/24
07/28
MK-8591A-052, NCT05630755: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
514
Europe, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/Islatravir, BIC/FTC/TAF, Bictegravir/Emtricitabine/Tenofovir Alafenamide, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
10/24
08/28
MK-8591A-033, NCT04776252 / 2020-001191-14: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

Active, not recruiting
3
2000
Europe, Canada, Japan, US, RoW
MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/27
10/27
NCT05705349: DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
Merck Sharp & Dohme LLC
HIV-1 Infection
10/25
08/29
MK-8591A-054, NCT05766501: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir
Merck Sharp & Dohme LLC
HIV Infection
12/25
09/28
MK-8591A-028, NCT04295772 / 2019-003597-10: Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg

Completed
2
42
Europe, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir
Merck Sharp & Dohme LLC
HIV-1 Infection
12/21
01/23
2017-000437-32: Dose Ranging Trial of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine (3TC)

Not yet recruiting
2
120
Europe
MK-8591, Doravirine, Doravirine/Lamivudine/Tenofovir disoproxil fumarate, Epivir, MK-8591A, MK-8591, MK-1439, MK-1439A, MK-8591A, Capsule, Film-coated tablet, Epivir
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT06719570: A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Completed
1
24
US
MK-8591A, Doravirine/Islatravir (DOR/ISL) Fixed-Dose Combination (FDC), Islatravir, MK-8591, ISL, Doravine, MK-1439, DOR
Merck Sharp & Dohme LLC
Healthy
03/24
03/24

Download Options